Literature DB >> 27613285

Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.

Jasvinder A Singh1,2,3,4.   

Abstract

Biologic use is a major advance in the treatment of several autoimmune conditions, including rheumatoid arthritis. In this review, we summarize key studies of serious/hospitalized infections in rheumatoid arthritis (RA). RA is a risk factor for infections. High RA disease activity is associated with higher risk of serious infection. The risk of serious infections with tumor necrosis factor inhibitor (TNFi) biologics is increased in the first 6 months of initiating therapy, and this risk was higher compared to the use of traditional disease-modifying anti-rheumatic drugs (DMARDs). Emerging data also suggest that biologics may differ from each other regarding the risk of serious or hospitalized infections. Past history of serious infections, glucocorticoid dose, and older age were other important predictors of risk of serious infections in patients treated with biologics.

Entities:  

Keywords:  Abatacept; Adalimumab; Biologics; Certolizumab pegol; Etanercept; Golimumab; Hospitalized infection; Infection; Infliximab; Non-TNF biologic; Rituximab; Serious infection; TNFi; Tocilizumab; Tumor-necrosis factor inhibitors

Mesh：

Substances：

Year:  2016        PMID： 27613285     DOI： 10.1007/s11926-016-0609-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  27 in total

Review 1.  Biologic therapies in rheumatoid arthritis.

Authors:  K J Bulpitt
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.

Authors:  Huifeng Yun; Fenglong Xie; Elizabeth Delzell; Emily B Levitan; Lang Chen; James D Lewis; Kenneth G Saag; Timothy Beukelman; Kevin L Winthrop; John W Baddley; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

3.  Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register.

Authors:  S Odegård; A Finset; T K Kvien; P Mowinckel; T Uhlig
Journal:  Scand J Rheumatol       Date:  2005 Nov-Dec       Impact factor: 3.641

4.  The risk of hospitalized infection in patients with rheumatoid arthritis.

Authors:  Allison L Smitten; Hyon K Choi; Marc C Hochberg; Samy Suissa; Teresa A Simon; Marcia A Testa; K Arnold Chan
Journal:  J Rheumatol       Date:  2008-02-01       Impact factor: 4.666

Review 5.  Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Jasvinder A Singh; Chris Cameron; Shahrzad Noorbaloochi; Tyler Cullis; Matthew Tucker; Robin Christensen; Elizabeth Tanjong Ghogomu; Doug Coyle; Tammy Clifford; Peter Tugwell; George A Wells
Journal:  Lancet       Date:  2015-05-11       Impact factor: 79.321

6.  Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Authors:  Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis
Journal:  JAMA       Date:  2011-11-06       Impact factor: 56.272

Review 7.  Quality of life in rheumatoid arthritis.

Authors:  T K Kvien; T Uhlig
Journal:  Scand J Rheumatol       Date:  2005 Sep-Oct       Impact factor: 3.641

8.  Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Authors:  Mark C Genovese; Stanley Cohen; Larry Moreland; Deborah Lium; Sean Robbins; Richard Newmark; Pirow Bekker
Journal:  Arthritis Rheum       Date:  2004-05

9.  Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment.

Authors:  A Finckh; H K Choi; F Wolfe
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

Review 10.  A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis.

Authors:  Leslie Goh; Teresa Jewell; Catherine Laversuch; Ash Samanta
Journal:  Rev Bras Reumatol       Date:  2013 Nov-Dec
View more
  14 in total

Review 1.  Applications of RNA interference in the treatment of arthritis.

Authors:  Muhammad Farooq Rai; Hua Pan; Huimin Yan; Linda J Sandell; Christine T N Pham; Samuel A Wickline
Journal:  Transl Res       Date:  2019-07-10       Impact factor: 7.012

2.  Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.

Authors:  Klervi Golhen; Carolyn Winskill; Cynthia Yeh; Nancy Zhang; Tatjana Welzel; Marc Pfister
Journal:  Front Pediatr       Date:  2022-06-21       Impact factor: 3.569

3.  Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India.

Authors:  S Chandrashekara; Vineeta Shobha; Vijay Rao; Anu Desai; Ramesh Jois; B G Dharmanand; Sharath Kumar; Pradeep Kumar; Chethana Dharmapalaiah; Kurugodu Mathada Mahendranath; Shiva Prasad; Manisha Ashwin Daware; Yogesh Singh; Uma Karjigi; S Nagaraj; K R Anupama
Journal:  Rheumatol Int       Date:  2019-01-25       Impact factor: 2.631

4.  Activity of rheumatoid arthritis correlates with oral inflammatory burden.

Authors:  Leena Äyräväinen; Anna Maria Heikkinen; Antti Kuuliala; Kirsi Ahola; Riitta Koivuniemi; Jaakko Peltola; Anni Suomalainen; Eeva Moilanen; Mari Hämäläinen; Leena Laasonen; Jukka H Meurman; Marjatta Leirisalo-Repo
Journal:  Rheumatol Int       Date:  2018-07-24       Impact factor: 2.631

5.  Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.

Authors:  Xintong Li; Kathleen M Andersen; Hsien-Yen Chang; Jeffrey R Curtis; G Caleb Alexander
Journal:  Ann Rheum Dis       Date:  2019-10-31       Impact factor: 19.103

Review 6.  The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis.

Authors:  Federico Biscetti; Andrea Flex; Stefano Alivernini; Barbara Tolusso; Elisa Gremese; Gianfranco Ferraccioli
Journal:  Mediators Inflamm       Date:  2017-10-23       Impact factor: 4.711

7.  COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic.

Authors:  Giulia Costanzo; William Cordeddu; Luchino Chessa; Stefano Del Giacco; Davide Firinu
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

8.  Bronchiectasis is as crucial as interstitial lung disease in the severe pneumonia that occurs during treatment with biologic DMARDs in rheumatoid arthritis: a retrospective cohort study in a single facility.

Authors:  Kyoko Honne; Masashi Bando; Makiko Naka Mieno; Masahiro Iwamoto; Seiji Minota
Journal:  Rheumatol Int       Date:  2021-07-12       Impact factor: 3.580

9.  RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus.

Authors:  Laura Mandik-Nayak; James B DuHadaway; Jennifer Mulgrew; Elizabeth Pigott; Kaylend Manley; Summer Sedano; George C Prendergast; Lisa D Laury-Kleintop
Journal:  Dis Model Mech       Date:  2017-09-07       Impact factor: 5.758

Review 10.  Managing rheumatic diseases during COVID-19.

Authors:  Amit P Ladani; Muruga Loganathan; Abhijeet Danve
Journal:  Clin Rheumatol       Date:  2020-09-08       Impact factor: 3.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.